SEEL Seelos Therapeutics
- 0.3180
- -0.0213-6.28%
Seelos Therapeutics News
On April 30, Seelos Therapeutics Inc Announced A Reduction In Its Workforce That Affected ~33% Of Its Current Employees; Company Received Bid Notice From Nasdaq Stock Market
On April 30, Seelos Therapeutics Inc Announced A Reduction In Its Workforce That Affected ~33% Of Its Current Employees; Company Received Bid Notice From Nasdaq Stock Market
Seelos Therapeutics to Cut Workforce by 33%, Reduce Working Hours
By Sabela Ojea Seelos Therapeutics is cutting its workforce by about 33% and reducing the working hours of employees as it looks to shift its strategy toward mental-health initiatives. The pharmaceu
Seelos Therapeutics Navigates Financial and Board Changes
12 Health Care Stocks Moving In Monday's After-Market Session
GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings
Psychedelic Drug Developers Could Benefit From NIH Funding for Chronic Pain
Seelos Therapeutics Appoints Richard Pascoe As Chairman Of The Board
Press Release: Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations PR Newswire NEW YORK, April 29,
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersXTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 95.8% to $2.04 during Wednesday's regular session. The company's market cap stands at $11.0 million. Etao International Co (NASDAQ:E
Optimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial Results
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersOntrak (NASDAQ:OTRK) shares increased by 97.6% to $0.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.3 million. Fusion Pharmaceuticals (NASDAQ:FUSN)
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
Tuesday, Seelos Therapeutics Inc (NASDAQ:SEEL) provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. The study was designed to evaluate SLS-005 (IV trehalose), a low molecula
Seelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary Endpoints
By Chris Wack Seelos Therapeutics shares were down 47% to 48 cents in premarket trading after a Phase 2/3 trial for SLS-005 for amyotrophic lateral sclerosis failed to meet its primary endpoints. Th
Seelos Falls as Lead Drug Fails in ALS Trial
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersOntrak (NASDAQ:OTRK) shares rose 173.2% to $0.52 during Tuesday's pre-market session. The company's market cap stands at $14.3 million. Fusion Pharmaceuticals (NASDAQ:FUSN) shares rose 97.46% t
Seelos Therapeutics Says The Study Did Not Meet Statistical Significance In The Primary And Secondary Endpoint In The Full Analysis Set
Seelos Therapeutics Says The Study Did Not Meet Statistical Significance In The Primary And Secondary Endpoint In The Full Analysis Set
Seelos Therapeutics Provides Update On Top-Line Results From Its Amyotrophic Lateral Sclerosis Study With SLS-005
Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today pro
Seelos Therapeutics Provides Update on Top-Line Results From Its Amyotrophic Lateral Sclerosis (ALS) Study With SLS-005 (IV Trehalose)
NEW YORK, March 19, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sy
Seelos Therapeutics Files for 3.4M Shares Secondary Offering
Mind Medicine Sends Psychedelic Stocks Higher After FDA Status for LSD Formulation
Oregon House Passes Bill to End Hard Drug Decriminalization
There are many factors in setting drug policy, which often center around the benefits or detriments to a society and its economy.
Analysis
Price Target
No Data
